434 related articles for article (PubMed ID: 28095712)
1. Current views on the potential for development of a HIV vaccine.
Cohen KW; Frahm N
Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
[TBL] [Abstract][Full Text] [Related]
2. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
3. Progress in HIV vaccine development.
Hsu DC; O'Connell RJ
Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
[TBL] [Abstract][Full Text] [Related]
4. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
O'Connell RJ; Kim JH; Excler JL
Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
[TBL] [Abstract][Full Text] [Related]
5. [Advances in the Immunogenic Design of HIV-1 Vaccine].
Zhang X; Wang T; Yu X
Bing Du Xue Bao; 2016 Jan; 32(1):88-92. PubMed ID: 27295889
[TBL] [Abstract][Full Text] [Related]
6. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
Stephenson KE; Wagh K; Korber B; Barouch DH
Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
[TBL] [Abstract][Full Text] [Related]
7. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 phylogenetics and vaccines.
Rolland M
Curr Opin HIV AIDS; 2019 May; 14(3):227-232. PubMed ID: 30925535
[TBL] [Abstract][Full Text] [Related]
9. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
10. Translational research insights from completed HIV vaccine efficacy trials.
Tieu HV; Rolland M; Hammer SM; Sobieszczyk ME
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S150-4. PubMed ID: 23764628
[TBL] [Abstract][Full Text] [Related]
11. Advances in HIV-1 Vaccine Development.
Gao Y; McKay PF; Mann JFS
Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
[TBL] [Abstract][Full Text] [Related]
12. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.
Wren L; Kent SJ
Hum Vaccin; 2011 Apr; 7(4):466-73. PubMed ID: 21389779
[TBL] [Abstract][Full Text] [Related]
13. Prospects for a Globally Effective HIV-1 Vaccine.
Excler JL; Robb ML; Kim JH
Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
[TBL] [Abstract][Full Text] [Related]
14. New concepts in HIV-1 vaccine development.
Stephenson KE; D'Couto HT; Barouch DH
Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
[TBL] [Abstract][Full Text] [Related]
15. Adjuvants: tailoring humoral immune responses.
McElrath MJ
Curr Opin HIV AIDS; 2017 May; 12(3):278-284. PubMed ID: 28257301
[TBL] [Abstract][Full Text] [Related]
16. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
17. Immunological mechanisms of inducing HIV immunity in infants.
Fouda GG; De Paris K; Levy O; Marchant A; Gray G; Permar S; Marovich M; Singh A
Vaccine; 2020 Jan; 38(3):411-415. PubMed ID: 31761501
[TBL] [Abstract][Full Text] [Related]
18. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
Koff WC
Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
[TBL] [Abstract][Full Text] [Related]
19. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
[TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
